Author pages are created from data sourced from our academic publisher partnerships and public sources.
Intradermal influenza vaccine for older adults: a randomized controlled multicenter phase III study.
In a 3-year, randomized, controlled, open-label phase III trial enrolling 3707 adults aged > or = 60 years we evaluated whether the immunogenicity of an intradermal trivalent inactivated seasonal… Expand
Immunogenicity, large scale safety and lot consistency of an intradermal influenza vaccine in adults aged 18–60 years: Randomized, controlled, Phase III trial
- R. Arnou, P. Eavis, José-Ramon De Juanes Pardo, A. Ambrozaitis, M. Kazek, F. Weber
- Human vaccines
- 1 April 2010
Background: Vaccination is the most effective way of reducing the large health and economic burden of influenza, yet vaccination coverage remains low, particularly among non-elderly adults.… Expand
Intradermal Influenza Vaccine Elicits Superior Immunogenicity in Adults Aged ≥60 Years: A Randomized Controlled Phase 3 Trial
28% (1360/4890); 45% (520/1154) in meningitis and 22% (840/3736) in other IPD cases (p < 0.001). Of patients tested for HIV, HIV-seroprevalence was 512/664 (77%) amongst meningitis cases and… Expand
Safety and Immunogenicity of a novel intradermal influenza vaccine in elderly adults (aged >60 years): randomised controlled phase 3 trial results